醫(yī)療特長(zhǎng):
從事惡性腫瘤綜合治療多年,,擅長(zhǎng)鼻咽癌,、喉癌、下咽癌,、口咽癌,、副鼻竇惡性腫瘤的放射治療及個(gè)體化綜合治療。
教育經(jīng)歷:
2011.9 - 2014.07 中山大學(xué)附屬第一醫(yī)院,,腫瘤學(xué)(放射治療方向),,博士
2012.9 - 2012.12 美國(guó)Albert Einstein醫(yī)學(xué)院Beth Israel癌癥中心,,Clinical Observer
2004.9 - 2007.7 中山大學(xué)腫瘤防治中心,腫瘤學(xué)(放射治療方向),,碩士
1998.9 - 2003.7 鄭州大學(xué),,臨床醫(yī)學(xué),學(xué)士
工作經(jīng)歷:
2014.07-至今 中山大學(xué)附屬第一醫(yī)院放射治療科工作
2010.07-2011.08 中山大學(xué)附屬第五醫(yī)院放療科,,住院醫(yī)師
2007.08-2010.07 中山大學(xué)腫瘤防治中心,,放射腫瘤學(xué)專科培訓(xùn)醫(yī)師,。
代表作:
- Induction chemotherapy regimen of docetaxel plus cisplatin versus docetaxel, cisplatin plus fluorouracil followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Preliminary results of an open-label, noninferiority, multicentre, randomised, controlled phase 3 trial. Lancet Eclinicalmedicine,,2022; IF=17.033
- Pretreatment BMI as an independent prognostic factor in patients with locoregionally advanced NPC treated with chemoradiotherapy: Findings from a randomized trial. EJC,,2013,; IF=10.002
- Association between Pretreatment Serum High-density Lipoprotein Cholesterol and Treatment Outcomes in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma Treated with Chemoradiotherapy: Findings from a Randomised Trial.JOC,2019,; IF=4.478